particles count.

2018 BIO International, Boston

Meet attyloid at BIO.NRW booth 1501-2

attyloid GmbH founded

We proudly announce that we recently founded the spin-off company attyloid GmbH (i.G.). The founders are (from left to right) Oliver Bannach, Andreas Kulawik, Dieter Willbold, Christian Zafiu and Detlev Riesner.

Deutsche Biotechnologietage 2018

Meet attyloid at the Deutsche Biotechnologietage

Oliver Bannach is "Düsseldorf Citizen of the Year 2017"

Oliver Bannach, designated CEO of attyloid, was recently awarded “Düsseldorf Citizen of the Year 2017” to acknowledge his research on Alzheimer’s disease diagnostics as well as his spin-off activities.

ISO 9001:2015 certification

attyloid announces that its mother institution ICS-6 of Forschungszentrum Jülich has recently obtained ISO 9001:2015 quality certification.

BioEurope Berlin 2017

Meet attyloid at the BIO.NRW booth
attyloid

Company profile

attyloid is a spin-off from Forschungszentrum Jülich and Heinrich-Heine University Düsseldorf. attyloid offers its proprietary sFIDA platform technology for the ultrasensitive quantitation of protein particles. The ISO9001:2015-embedded sFIDA technology is fully automized and scalable. Building on a strong scientific expertise in protein misfolding and aggregation, we focus our business model on aggregate quantitation for development and QC of biologicals. attyloid offers sFIDA to pharmaceutical and biotech companies.

sFIDA Technology

sFIDA stands for surface-based fluorescence intensity distribution analysis. The assay uses a combination of aggregate-binding antibodies and fluorescence microscopy imaging. First, protein aggregates are captured from the sample and fixed to a glass sur- face. After unbound sample components are removed, detection antibodies labeled with two fluorescent dyes are added. A laser focus scans the surface and the highly decorated aggregates show bursts of fluorescent light in two color channels.

The assay is currently in the process of validation and optimization for the demands of high-throughput measurements. MORE

attyloid offers its proprietary sFIDA technology for development and quality control of biologicals.

Founders and Idea

Since 2014 our project has been supported by the VIP-Program of the German Federal Ministry of Education. In 2016 we obtained funding by the Helmholtz Enterprise Program and by Start-up NRW to commericalize the sFIDA technolgy as a spin-off company.

attyloid draws on a strong team of founders with expertise in Life Science, Health Care and Corporate Development.

Dr. Oliver Bannach

Dr. Oliver Bannach

CEO

 Dr. Andreas Kulawik

Dr. Andreas Kulawik

COO

Dr. Christian Zafiu

Dr. Christian Zafiu

CSO

Prof. em. Dr. Dr. h.c. Detlev Riesner

Prof. em. Dr. Dr. h.c. Detlev Riesner

Supervisory Board

Prof. Dr. Dieter Willbold

Prof. Dr. Dieter Willbold

Supervisory Board Chairman

Get in Touch

Privacy Policy*

5 + 2 =

attyloid GmbH
Elsa-Brändström-Str. 34
40595 Düsseldorf
Germany

Mail: info@attyloid.com

Fon: +49 (0) 211 81-10377

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!

Help

Help

To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice

Back